Comparative Pharmacology
Head-to-head clinical analysis: ETHOSUXIMIDE versus VIGAFYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHOSUXIMIDE versus VIGAFYDE.
ETHOSUXIMIDE vs VIGAFYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethosuximide reduces the frequency of spike-and-wave discharges in absence seizures by blocking T-type calcium channels in thalamic neurons, thereby stabilizing neuronal membrane and preventing rhythmic burst firing.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
Adults: 500 mg orally twice daily initially, increase by 250 mg every 4-7 days as needed; maintenance dose 1-2 g/day divided into 2-4 doses. Maximum 1.5 g/dose or 3 g/day.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 60 hours (range 40–60 hours) in adults; children may have shorter half-life (~30–40 hours). Long half-life allows once- or twice-daily dosing.
Clinical Note
moderateEthosuximide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Fluconazole
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
Primarily renal excretion; ~20% as unchanged ethosuximide and ~50% as conjugated metabolite (glucuronide plus minor hydroxymetabolites). Less than 5% eliminated via feces.
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Ethosuximide."